search

Active clinical trials for "Hypertension"

Results 2421-2430 of 5863

Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved...

HypertensionPulmonary1 more

The primary objective of this study is to • Assess the pharmacodynamic profile of riociguat in subjects with symptomatic pulmonary hypertension and heart failure with preserved ejection fraction The secondary objectives of this study are to Assess safety and tolerability of riociguat in this study population Assess changes in dimensions of left and right ventricles and cardiac function parameters using cardiac magnetic resonance imaging

Completed50 enrollment criteria

Study of CS-3150 in Patients With Severe Hypertension

Severe Hypertension

To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).

Completed7 enrollment criteria

The Treatment of Hepatocirrhosis and Portal Hypertension

Hepatic CirrhosisPortal Hypertension

This study compare the efficiency of partial splenic embolization +endoscopical therapy with endoscopical therapy alone in gastroesophageal variceal haemorrhage accompanied with splenomegaly or hypersplenism of hepatocirrhosis and portal hypertension treatment.

Completed12 enrollment criteria

Arterial Stiffness as a Predictor of Response to Renal Sympathetic Denervation

Therapy Resistant Arterial Hypertension

This trial is designed to establish invasive and non-invasive measures of arterial stiffness as potential predictors of treatment response to renal sympathetic denervation

Completed7 enrollment criteria

Renal Nerves Stimulation Study

HypertensionRenal Denervation

Study design: Investigator initiated, single centre, feasibility study Main objectives are twofold: To investigate the feasibility of RNS in patients with therapy resistant hypertension, which is assessing the functional distribution of renal nerves using 3D imaging and differential pacing modalities. To investigate the blood pressure responses and cardiac excitable properties to RNS, and subsequently perform a RDN procedure, guided by 3D mapping by two different techniques e.g. RNS-checked RDN and RNS-guided RDN procedures. Study population: 40 patients (18 - 80 yr old)

Completed14 enrollment criteria

Lifestyle Intervention for Treating Systemic Hypertension in Primary Care Setting

Hypertension

The Canadian hypertension education program recommends increased physical activity, adoption of the Dietary Approaches to Stop Hypertension (DASH) diet, and reduction in sodium and alcohol intake for treatment and prevention of hypertension. Objective: To describe patients participating in an interdisciplinary lifestyle intervention to reduce blood pressure in a family medicine primary care setting. Design: Descriptive study. Participants: The study aims to recruit 60 sedentary hypertensive patients to participate in a 6-month randomized-controlled trial. To be eligible, patients must be ≥18 years of age, sedentary (7-day measured steps/day and self-report), hypertensive (based on 24-h ambulatory blood pressure measurements [ABPM]), non-smoker, non-diabetic and without dyslipidemia. Intervention: Patients are recruited by health care professionals of the family medicine unit and are thereafter randomized to one of four intervention groups: 1) standard medical care (control), 2) improved diet (DASH diet), 3) physical activity, or 4) both improved diet and physical activity. Patients are evaluated (pre, mid and post intervention), monitored, and educated by the interdisciplinary health care team that includes a physician, a kinesiologist, a nutritionist and a nurse, depending on the intervention group. T-tests and descriptive statistics were used to analyse data. This study will document the efficacy of a primary care lifestyle intervention program on cardiometabolic and hypertension risk factors.

Completed8 enrollment criteria

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

Primary Open-Angle Glaucoma (POAG)Ocular Hypertension (OHT)

Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or timolol 0.5% twice per day for 12 weeks in adult subjects with Ocular Hypertension or Primary Open-Angle Glaucoma. All subjects who meet the study's enrollment criteria following Screening will undergo washout of all prohibited medications, including their routine glaucoma medications. During the Placebo Run-In Period, placebo is administered twice daily to both eyes in all subjects. During the Treatment Period, study drug is applied to both eyes for a total of 12 weeks followed by an Observation Period of approximately 7 days wherein no study eye drops are instilled. The purpose of the study is to assess the efficacy, tolerability, and safety of binocular topical application of trabodenoson ophthalmic formulation 3.0% or 6.0% QD or 4.5% BID for 12 weeks. Timolol is being included in the trial in order to have an active control to ensure the integrity of the trial from an efficacy perspective; the primary comparator for all statistical purposes is the placebo arm.

Completed6 enrollment criteria

Hypertension With Unsatisfactory Sleep Health

InsomniaHypertension

Insomnia and hypertension are common health problems that often occur together and influence each other. This practical, low-cost, clinical trial will evaluate two behavioral treatments for insomnia (a brief intervention with therapist contact and a self-guided Internet intervention) compared to usual care. Participants will be recruited using the electronic health record in their primary care physicians' offices, and will be evaluated for sleep, blood pressure, and health outcomes after 9 weeks, 6 months, and 12 months.

Completed21 enrollment criteria

Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject

Hypertension

This clinical trial was evaluated to compare the safety and pharmacokinetics of Besylsartan with Amosartan, which was available commercially after single oral dose in healthy male subjects.

Completed8 enrollment criteria

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients...

Pulmonary Arterial Hypertension

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.

Completed52 enrollment criteria
1...242243244...587

Need Help? Contact our team!


We'll reach out to this number within 24 hrs